TOP 10



STI PROPHYLAXIS -DOXYCYCLINE AS PREP

- DOXYVAC in France
- DOXYPEP in the US
- dPEP in Kenya
- DaDHS trial in Canada
- Syphilaxis Study in Australia
- DISCO Study in Canada



REPRESENTATION
OF A PERSON
LIVING WITH HIV
IN THE MEDIA
EASTENDERS





FAST TRACK CITIES

OPT OUT BBV TESTING IN ED

ED BBV testing: results April 2022 – March 2023

Results	New	Previously	In care	Reinfection
	diagnosis	diagnosed		
		not in care		
HIV	343	209	4,396	n/a
HBV	1,186	156	681	n/a
HCV	469	108	135	15
Total	1,998	473	5,212	15

Subject to UKHSA validation. New defined as new to clinic and not disclosing under care.

- In first year found about 2,000 new diagnoses and approaching 500 previously diagnosed not in care.
- Avoiding one HIV transmission saves £140k.
- Hep B surprisingly large number of new diagnoses.



HIV PROPHYLAXIS

TAF GAINS APPROVAL FOR USE AS PREP

NHS England approves the reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV

MDT decision

The individual cannot take the usual first-line PrEP therapy due to risk factors to TD-FTC use.


Risk factors for TD-FTC use:

- Individuals with a reduction in estimated glomerular filtration (eGFR3 < 60 ml/min) and clinical assessment suggests that TAF-FTC would have a lower risk profile than TD-FTC OR
- Individuals with proven renal toxicity with TD-FTC (acute or chronic) OR
- Individuals with osteoporosis who are at a high risk for fractures OR
- Individuals who are < 18 years OR
- Individuals with an eGFR ≥ 60 ml/min in whom:
- A progressive reduction in glomerular filtration rate on TD-FTC is seen AND
- Significant concurrent medical issues or monitoring/prescribing concerns which suggest TAF-FTC would have a lower risk profile to TD-FTC.

Exclusion criteria:


 Individuals with contraindications or the potential for significant drug interactions to TAF- FTC or TD-FTC as outlined in the Summary of Product Characteristics (SPC)

LONG ACTING ANTI-RETROVIRALS





CELEBRATING
THE AFRICAN
CONTRIBUTIO
N TO THE UK
HIV
RESPONSE.
OUR STORIES
TOLD BY US





3 DRUGS FOR EXTENSIVE DRUG RESISTANCE

Fostemsavir:

attachment inhibitor (daily in combination with other ARVs)
Approved by NHS England

• Ibalizumab:

monoclonal antibody (every 2 weeks in combination with other ARVs)


Approved by EMA, directly commissioned by NHS England (not through national reimbursement, would be of limited value to the NHS)

• Lenacapavir:

Capsid inhibitor (every 6 months – in combination with?)


Possibility to use with broadly neutralising antibodies to establish a 6 monthly regimen (CROI)?

FIRST LIVE LIVER TRANSPLANT FROM A DONOR LIVING WITH HIV/HCV COINFECTION





LIFE EXPECTANCY INCREASES BY 30 TO 40 YEARS FOR PEOPLE ON ART





STANDARDS OF MENTAL HEALTH CARE FOR PEOPLE LIVING WITH HIV

PRE-CONSULTATION OF STAKEHOLDERS AND NEXT STEPS

- · Consultation with stakeholders has been concluded
- Final report has been drafted
- Guide to needed changes and mapping on how to incorporate these
- More funding needed to put together a writing group



NHIVNA 25 YEARS OF SUCCESSFUL CONFERENCES



Audit & Research + Awards, Grants & Scholarships + Competencies, Guidelines & Publications + Conferences & Events + NHIVNA Education + Resources +





Annual Conference 14-16 June 2023







VOTING

- Please scan the QR code and vote ONLY the 3 you consider more important
- Alternatively, please follow the link: slido.com and use the hashtag: NHIVNA to log in and vote

